<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148264">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01170247</url>
  </required_header>
  <id_info>
    <org_study_id>201006786</org_study_id>
    <secondary_id>University of Iowa</secondary_id>
    <nct_id>NCT01170247</nct_id>
  </id_info>
  <brief_title>Intranasal Ketamine Versus Intramuscular Ketamine for Procedural Sedation in Pediatric Patients</brief_title>
  <official_title>Intranasal Ketamine Versus Intramuscular Ketamine for Procedural Sedation: A Prospective Randomized, Double-blinded, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if intranasal ketamine is equally as effective and
      safe as intramuscular ketamine for procedural sedation in pediatric patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of enrollment
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of sedation (Observation Scale of Behavioral Distress-Revised)</measure>
    <time_frame>Up to 60 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of sedation</measure>
    <time_frame>Minutes it take until the patient is cooperative enough for th procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to awakening</measure>
    <time_frame>Up to 60 minutes after completion of the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>From the time when the procedure is completed until the patient is discharged home</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction survey</measure>
    <time_frame>Approximately 24 hours after the completion of the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare provider satisfaction survey</measure>
    <time_frame>30 minutes after the procdure</time_frame>
    <description>Rate their satisfaction for the following questions: patient toleration of the medication, onset of sedation, comfort of patient during procedure, and adverse effects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Intranasal Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Intranasal Ketamine (100 mg/mL)</description>
    <arm_group_label>Intranasal Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Intramuscular Ketamine</description>
    <arm_group_label>Intramuscular Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pediatric patients age 2 to 17 years old

          -  have a laceration of 4 cm on the face or 7 cm on the remainder of the body

          -  Require procedural sedation to repair the laceration

        Exclusion Criteria:

          -  Patients with abnormal nasal physiology which would not allow for adequate medication
             delivery

          -  Unable to have a guardian present to consent on their behalf

          -  Allergy to ketamine

          -  Significant cardiac history (myocardial ischemia, heart failure, arrhythmias)

          -  Presenting with a head injury associated with possible intracranial hypertension

          -  Pregnancy

          -  Lacerations that require repair from a consult service
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Hogrefe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brett Faine, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Nugent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 11, 2012</lastchanged_date>
  <firstreceived_date>July 21, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Brett A Faine</investigator_full_name>
    <investigator_title>Clinical Pharmacy Specialist</investigator_title>
  </responsible_party>
  <keyword>Procedural Sedation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
